BBM-D101 gene therapy for boys with Duchenne muscular dystrophy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-arm, open-label Phase 1/2 trial giving one intravenous infusion of BBM-D101, an AAV-based gene addition therapy designed to deliver a therapeutic protein to muscle. Participants will be followed closely for 52 weeks for safety, tolerability, pharmacokinetics, pharmacodynamics, immune responses, and preliminary efficacy, with additional long-term safety and efficacy follow-up up to 5 years. Key procedures include motor function assessments, MRI, muscle biopsy, and laboratory monitoring; participants must be ambulatory boys aged 4 to under 9 with genetically confirmed DMD and acceptable AAV antibody and lab profiles. The study focuses on whether the delivered protein can support the dystrophin-associated complex and improve muscle function while monitoring for immune or other adverse effects.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. The Participants and/or his legal guardian must fully understand the purpose, nature, methods, and potential risks of the study, and sign a written informed consent form.
2. Ambulatory male subjects aged 4 years and above but under 9 years (4 years ≤ age \< 9 years).
3. Any mutation in the DMD gene confirmed by genetic testing
4. Serum creatine kinase (CK) during the screening period meets the study requirements.
5. Receiving stable, standard-dose glucocorticoids before screening.
6. The subject's AAV capsid antibodies meet the clinical trial requirements.
7. Able to cooperate with motor function assessment, MRI, and muscle biopsy as required by the study.
8. Laboratory test results during the screening period and at baseline meet the standards.
9. The subject and/or his legal guardian must fully understand the study procedures, be willing to actively cooperate, commit to high compliance with the protocol, and ensure that the subject attends all scheduled visits.

Exclusion Criteria:

1. Positive for hepatitis B surface antigen (HBsAg), hepatitis B virus deoxyribonucleic acid (HBV-DNA) ≥ 1000 U/mL, hepatitis C virus ribonucleic acid (HCV-RNA) positive, human immunodeficiency virus (HIV) positive, or positive for Treponema pallidum antibodies.
2. Currently receiving antiviral therapy for hepatitis B, hepatitis C, HIV, etc.
3. The investigator deems the subject has severe behavioral or cognitive disorders that may hinder participation in this study.
4. Poorly controlled asthma, or Duchenne Muscular Dystrophy (DMD) leading to significant decline in lung function, or recurrent infectious pneumonia that the investigator considers may affect respiratory function.
5. Left ventricular ejection fraction (LVEF) \< 50% or New York Heart Association (NYHA) cardiac function class ≥ III.
6. Severe or persistent arrhythmias (such as atrial fibrillation, frequent ventricular premature beats, ventricular bigeminy, ventricular trigeminy, severe bundle branch block, etc.), and congenital heart disease that is evaluated by the investigator as unsuitable for participation in this study.
7. Any changes in preventive/cardiomyopathy treatment (initiation of treatment, drug changes, dosing regimen changes, treatment interruption, termination, or restart) within 1 month before the infusion of the study drug.
8. History of liver diseases such as portal hypertension, splenomegaly, hepatic encephalopathy, liver fibrosis ≥ stage 3, or hepatic nodules/cysts found by ultrasound during screening, or elevated alpha-fetoprotein with clinical significance as determined by the investigator.
9. Severe infection (such as pneumonia, pyelonephritis, or meningitis) within 4 weeks before the treatment visit (enrollment may be postponed).
10. History of gene therapy or cell therapy (such as stem cell transplantation).
11. History of or current presence of autoimmune diseases, severe renal, gastrointestinal, neurological, or coagulation disorders, malignant tumors, or other diseases.
12. Other diseases that the investigator deems unsuitable for participation in this study.

Where it's running

• Peking Union Medical College Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Principal investigator: Yi Dai, MD — Peking Union Medical College Hospital
• Study coordinator: Hanyang Hu, Ph.D
• Email: huhanyang@beliefbiomed.com
• Phone: +86-021-33588288

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• VM100: a nutritional supplement to see if it improves quality of life for boys with Duchenne

  This Phase 2 study tests VM100, a nutritional drink, in boys aged 8 and up with Duchenne muscular dystrophy to see if it can improve quality of life and reduce fatigue.

  Recruiting Phase 2 University of Florida · Gainesville, Florida · NCT07766980

• Zeleciment Rostudirsen (DYNE-251) for Duchenne Muscular Dystrophy in Ambulatory Boys

  This trial tests whether intravenous Zeleciment Rostudirsen (DYNE-251) given every 4 weeks is safe and helps improve function in ambulatory boys with Duchenne muscular dystrophy who have a specific dystrophin gene mutation.

  Recruiting Phase 3 Dyne Therapeutics · Hillsborough, North Carolina · NCT07608432

• AOC 1044 in Duchenne Muscular Dystrophy with Exon 44 Skipping

  This study tests whether intravenous AOC 1044 helps boys with Duchenne muscular dystrophy caused by mutations amenable to exon 44 skipping.

  Recruiting at 20 sites Phase 3 Avidity Biosciences, Inc. · Westmead, New South Wales and 19 other locations · NCT07587242

• Machine-learning multi-sensor fall risk screening for Duchenne muscular dystrophy

  This project will try machine-learning and video/sensor methods to track upper limb movement and see if they can help detect fall risk in children and young adults with Duchenne muscular dystrophy.

  Recruiting Seoul National University Hospital · Seoul, Jongno · NCT07015632

• Combining exercise and tadalafil for treating Duchenne muscular dystrophy

  This study is testing if combining exercise with a medication called tadalafil can help boys with Duchenne muscular dystrophy improve their muscle function and blood flow.

  Recruiting Phase 2 University of Florida · Gainesville, Florida · NCT06290713

• Registry for patients with neuromuscular disorders in Switzerland

  This study is creating a database to help people in Switzerland with neuromuscular disorders, like DMD and SMA, get access to new treatments and participate in clinical trials.

  Recruiting at 19 sites University of Bern · Aarau, Canton of Aargau and 18 other locations · NCT05102916

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.